丹参川芎嗪注射液联合单硝酸异山梨酯缓释片治疗心肌缺血临床分析(1)
[摘要] 目的 通過对冠心病心肌缺血患者分别实施不同的治疗方案，观察其临床效果，探究不同方案的临床应用特点。 方法 从来该院诊治的2016年1月—2018年12月的心肌缺血患者中随机抽取87例，采用病例对照研究随机抽取对照组43例：采用丹参川芎嗪注射液治疗，观察组44例：采用丹参川芎嗪注射液+单硝酸异山梨酯缓释片治疗，观察两组心绞痛发作情况、疗效果情况、心电图变化情况。 结果 观察组治疗后心绞痛持续时间为(2.23±0.98)min/次低于对照组(4.74±2.15)min/次(t=11.264，P<0.05)，发作频率为(2.55±0.72)次/周低于对照组(4.63±2.17)次/周(t=11.864，P<0.05);观察组患者(93.18%)总有效率高于对照组(86.05%)(χ2=6.574，P<0.05);观察组ST段压低持续时间为(82.45±6.47)s低于对照组(132.52±12.64s)(t=9.678，P<0.05)，ST段压低发作次数为(8.83±1.31)次/周低于对照组(16.28±1.67)次/周(t=10.437，P<0.05)。 结论 丹参川芎嗪注射液联合单硝酸异山梨酯缓释片可有效治疗心肌缺血，降低心肌缺血持续时间、发作频率，提高治疗效果，降低ST段压低持续时间和ST段压低发作次数，是一项值得推广的临床治疗方案
, 百拇医药
[关键词] 丹参川芎嗪;单硝酸异山梨酯缓释片;心肌缺血
[中图分类号] R542 [文献标识码] A [文章编号] 1674-0742(2019)06(c)-0121-03
[Abstract] Objective To observe the clinical effects of different treatment options for patients with myocardial ischemia caused by coronary heart disease， and to explore the clinical application characteristics of different programs. Methods A total of 87 patients with myocardial ischemia from January 2016 to December 2018 in our hospital were randomly selected. A case-control study was used to randomly select 43 patients in the control group： treated with Danshen Ligustrazine Injection， and 44 patients in the observation group： Danshen ligustrazine injection + isosorbide mononitrate sustained-release tablets were used to observe the episodes of angina pectoris， treatment effect and ECG changes. Results The duration of angina pectoris in the observation group was (2.23±0.98)min/time lower than that in the control group (4.74±2.15)min/time (t=11.264， P<0.05)， and the frequency of attack was (2.55±0.72)times/week lower than the control group of (4.63±2.17)times/week (t=11.864， P<0.05); the total effective rate of the observation group (93.18%) was higher than that of the control group (86.05%)(χ2=6.574， P<0.05); The duration of depression was (82.45±6.47)s lower than that of the control group (132.52±12.64s)(t=9.678， P<0.05)， and the number of episodes of ST depression was (8.83±1.31)times/week lower than the control group (16.28±1.67)times/week (t=10.437， P<0.05). Conclusion Danshen Ligustrazine injection combined with isosorbide mononitrate sustained-release tablets can effectively treat myocardial ischemia， reduce the duration of myocardial ischemia， the frequency of attacks， improve the treatment effect， reduce the duration of ST-segment depression and the number of ST-segment depression episodes， which is a clinical treatment plan worth promoting., 百拇医药(任振强)
, 百拇医药
[关键词] 丹参川芎嗪;单硝酸异山梨酯缓释片;心肌缺血
[中图分类号] R542 [文献标识码] A [文章编号] 1674-0742(2019)06(c)-0121-03
[Abstract] Objective To observe the clinical effects of different treatment options for patients with myocardial ischemia caused by coronary heart disease， and to explore the clinical application characteristics of different programs. Methods A total of 87 patients with myocardial ischemia from January 2016 to December 2018 in our hospital were randomly selected. A case-control study was used to randomly select 43 patients in the control group： treated with Danshen Ligustrazine Injection， and 44 patients in the observation group： Danshen ligustrazine injection + isosorbide mononitrate sustained-release tablets were used to observe the episodes of angina pectoris， treatment effect and ECG changes. Results The duration of angina pectoris in the observation group was (2.23±0.98)min/time lower than that in the control group (4.74±2.15)min/time (t=11.264， P<0.05)， and the frequency of attack was (2.55±0.72)times/week lower than the control group of (4.63±2.17)times/week (t=11.864， P<0.05); the total effective rate of the observation group (93.18%) was higher than that of the control group (86.05%)(χ2=6.574， P<0.05); The duration of depression was (82.45±6.47)s lower than that of the control group (132.52±12.64s)(t=9.678， P<0.05)， and the number of episodes of ST depression was (8.83±1.31)times/week lower than the control group (16.28±1.67)times/week (t=10.437， P<0.05). Conclusion Danshen Ligustrazine injection combined with isosorbide mononitrate sustained-release tablets can effectively treat myocardial ischemia， reduce the duration of myocardial ischemia， the frequency of attacks， improve the treatment effect， reduce the duration of ST-segment depression and the number of ST-segment depression episodes， which is a clinical treatment plan worth promoting., 百拇医药(任振强)